Literature DB >> 20643248

Relationship of myocardial ischemia and injury to coronary artery disease in patients with supraventricular tachycardia.

Radhika Nandur Bukkapatnam1, Melissa Robinson, Samuel Turnipseed, Daniel Tancredi, Ezra Amsterdam, Uma Narasimhan Srivatsa.   

Abstract

Increase of serum troponin I and ST-segment depression are objective markers of myocardial ischemia/injury. Abnormalities of the 2 indicators have been associated with supraventricular tachycardia (SVT) but their relevance for diagnosing acute coronary syndrome and the presence of coronary artery disease (CAD) in this setting have not been clarified. Therefore, we sought to evaluate the frequency of CAD based on increased troponin I and ST-segment depression during SVT. During a 5-year period, 104 patients were admitted with a diagnosis of SVT, 80 of whom had troponin I testing, and 70 of these patients could be assessed for ST-segment changes. Thirty-seven patients (48%) had increased troponin I (mean 1.54 +/- 2.7 ng/dl, normal <or=0.07 ng/dl) and 46 patients (57%) had ST-segment depression >or=1.0 mm. There were no significant differences in baseline characteristics and clinical presentation of patients with and without troponin I increase or ST-segment depression. There was no difference in the diagnosis of CAD by noninvasive or invasive testing in patients with and without increased troponin I. More patients with than without ST-segment depression had evidence of CAD (22% vs none, p = 0.01), but after adjusting for covariates, ST-segment depression was not a significant predictor of CAD. In conclusion, increased troponin I and ST-segment depression are not significant markers of acute coronary syndrome in patients with SVT. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20643248     DOI: 10.1016/j.amjcard.2010.03.035

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Health care utilization among adenosine-sensitive supraventricular tachycardia patients presenting to the emergency department.

Authors:  Thomas A Dewland; Adam Oesterle; John Stein; Gregory M Marcus
Journal:  J Interv Card Electrophysiol       Date:  2017-06-10       Impact factor: 1.900

2.  Characterization of Cardiac Troponin Elevation in the Setting of Pediatric Supraventricular Tachycardia.

Authors:  Jeremy P Moore; Lisa Arcilla; Shuo Wang; Michael S Lee; Kevin M Shannon
Journal:  Pediatr Cardiol       Date:  2015-10-19       Impact factor: 1.655

Review 3.  Diagnosis and management of type II myocardial infarction: increased demand for a limited supply of evidence.

Authors:  Nathaniel R Smilowitz; Becky Naoulou; Steven P Sedlis
Journal:  Curr Atheroscler Rep       Date:  2015       Impact factor: 5.113

4.  Underuse of Catheter Ablation as First-Line Therapy for Supraventricular Tachycardia.

Authors:  Lucas Hollanda Oliveira; Mateus Dos Santos Viana; Christian Moreno Luize; Ricardo Sobral de Carvalho; Claudio Cirenza; Cristiano de Oliveira Dietrich; Luis Claudio Correia; Claudio das Virgens; Juliana Medeiros Filgueiras; Mauricio Barreto; Emerson Porto; Enia Coutinho; Ângelo de Paola
Journal:  J Am Heart Assoc       Date:  2022-06-03       Impact factor: 6.106

Review 5.  Challenges in high-sensitive troponin assay interpretation for intensive therapy.

Authors:  Humberto Andres Vaz; Raphael Boesche Guimaraes; Oscar Dutra
Journal:  Rev Bras Ter Intensiva       Date:  2019-02-28

6.  Paroxysmal Supraventricular Tachycardia.

Authors:  Casey Arnold; Carmen J Martinez Martinez
Journal:  Cureus       Date:  2019-06-11

7.  Turkish Society of Cardiology consensus paper on the rational use of cardiac troponins in daily practice.

Authors:  Kaan Okyay; Beste Özben Sadıç; Asife Şahinarslan; Murtaza Emre Durakoğlugil; Can Yücel Karabay; Semiha Emel Eryüksel; Özlem Gülbahar; Abdullah Tekin; Aylin Yıldırır; Bülent Görenek; Oğuz Yavuzgil; Ali Serdar Fak
Journal:  Anatol J Cardiol       Date:  2019-04-19       Impact factor: 1.596

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.